Wall Street Zen Upgrades Cytokinetics (NASDAQ:CYTK) to "Hold"

Key Points

• Wall Street Zen upgraded Cytokinetics from “sell” to “hold”, adding to a generally constructive analyst backdrop for the stock.
• Several firms recently raised their price targets, and the consensus view now sits at “Moderate Buy” with an average target price of $97.25.
• Cytokinetics reported quarterly EPS in line with expectations while revenue beat estimates sharply, and the company also completed a public offering that raised about $805 million in gross proceeds.

Cytokinetics (NASDAQ:CYTK - Get Free Report) was upgraded by equities researchers at Wall Street Zen from a "sell" rating to a "hold" rating in a report issued on Saturday.

Other analysts also recently issued reports about the company. JPMorgan Chase & Co. boosted their target price on Cytokinetics from $74.00 to $75.00 and gave the stock an "overweight" rating in a research report on Tuesday, March 17th. UBS Group set a $119.00 target price on Cytokinetics in a research report on Wednesday. Needham & Company LLC boosted their target price on Cytokinetics from $85.00 to $102.00 and gave the stock a "buy" rating in a research report on Tuesday. Royal Bank Of Canada boosted their target price on Cytokinetics from $101.00 to $119.00 and gave the stock an "outperform" rating in a research report on Wednesday. Finally, Morgan Stanley boosted their target price on Cytokinetics from $90.00 to $103.00 and gave the stock an "overweight" rating in a research report on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $97.25.

Cytokinetics Stock Performance

CYTK opened at $76.91 on Friday. The business's fifty day moving average is $64.21 and its two-hundred day moving average is $63.86. The company has a market cap of $9.57 billion, a price-to-earnings ratio of -11.24 and a beta of 0.38. Cytokinetics has a one year low of $29.31 and a one year high of $80.20.

Cytokinetics (NASDAQ:CYTK - Get Free Report) last posted its earnings results on Tuesday, May 5th. The biopharmaceutical company reported ($1.67) EPS for the quarter, hitting analysts' consensus estimates of ($1.67). The firm had revenue of $19.36 million for the quarter, compared to analysts' expectations of $8.52 million. The firm's revenue for the quarter was up 1112.5% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($1.36) earnings per share. On average, analysts predict that Cytokinetics will post -6.34 EPS for the current fiscal year.

Insider Transactions at Cytokinetics

In other news, EVP Fady Ibraham Malik sold 12,033 shares of the business's stock in a transaction on Tuesday, March 17th. The stock was sold at an average price of $62.15, for a total value of $747,850.95. Following the completion of the transaction, the executive vice president directly owned 153,902 shares of the company's stock, valued at $9,565,009.30. The trade was a 7.25% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Robert I. Blum sold 36,601 shares of the business's stock in a transaction on Tuesday, March 17th. The stock was sold at an average price of $62.15, for a total value of $2,274,752.15. Following the completion of the transaction, the chief executive officer directly owned 430,330 shares of the company's stock, valued at approximately $26,745,009.50. This trade represents a 7.84% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 169,976 shares of company stock valued at $10,710,369 over the last three months. 2.60% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Cytokinetics

A number of institutional investors have recently made changes to their positions in the stock. Bank of Montreal Can raised its holdings in shares of Cytokinetics by 1.2% in the fourth quarter. Bank of Montreal Can now owns 13,292 shares of the biopharmaceutical company's stock worth $845,000 after acquiring an additional 160 shares during the last quarter. Kennedy Capital Management LLC increased its stake in Cytokinetics by 1.2% in the fourth quarter. Kennedy Capital Management LLC now owns 13,183 shares of the biopharmaceutical company's stock valued at $838,000 after purchasing an additional 162 shares during the last quarter. UMB Bank n.a. increased its stake in Cytokinetics by 10.6% in the third quarter. UMB Bank n.a. now owns 1,762 shares of the biopharmaceutical company's stock valued at $97,000 after purchasing an additional 169 shares during the last quarter. Northwestern Mutual Wealth Management Co. increased its stake in Cytokinetics by 46.0% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 543 shares of the biopharmaceutical company's stock valued at $35,000 after purchasing an additional 171 shares during the last quarter. Finally, Vident Advisory LLC increased its stake in Cytokinetics by 1.4% in the fourth quarter. Vident Advisory LLC now owns 16,455 shares of the biopharmaceutical company's stock valued at $1,046,000 after purchasing an additional 234 shares during the last quarter.

Cytokinetics News Summary

Here are the key news stories impacting Cytokinetics this week:

• Positive Sentiment: Cytokinetics completed its public offering and sold 11.34 million shares, including full exercise of the underwriters’ option, raising about $805 million in gross proceeds. Article Title
• Positive Sentiment: Analysts remained constructive, with Piper Sandler and Raymond James reiterating bullish/hold views, while Wells Fargo raised its price target to $105 from $95, signaling continued confidence in the company’s longer-term outlook.
• Positive Sentiment: Coverage highlighting that Cytokinetics beat earnings expectations and that analysts have been lifting forecasts may also be helping sentiment around the stock.
• Neutral Sentiment: The company’s Q1 results presentation and offering-related disclosures keep investor attention focused on execution and pipeline development rather than any immediate operational surprise. Article Title
• Negative Sentiment: The recent stock sale increases share count and dilutes existing holders, which can pressure the stock despite the cash infusion.
• Negative Sentiment: Insider selling remains a headwind for sentiment, with an executive recently selling shares and broader insider activity showing only sales over the past several months. Article Title

About Cytokinetics

Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.

The company's most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.